CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang

Cancer Research and Treatment. 2018;50(3):835-842. Published online 2017 August 29 DOI: https://doi.org/10.4143/crt.2017.303

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang

Cancer Research and Treatment. 2018;50(3):835-842

Link1

Link2 Link3

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors

J.-C. Soria, J. Cortes, C. Massard, J.-P. Armand, D. De Andreis, S. Ropert, E. Lopez, A. Catteau, J. James, J.-F. Marier, M. Beliveau, R.E. Martell, J. Baselga

Annals of Oncology. 2012;23(2):463-471

Link1 Link2 Link3

Corrections to “Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors”

J.-C. Soria, J. Cortes, C. Massard, J.-P. Armand, D. De Andreis, S. Ropert, E. Lopez, A. Catteau, J. James, J.-F. Marier, M. Beliveau, R.E. Martell, J. Baselga

Annals of Oncology. 2019;30(6):1020

Link1 Link2 Link3

EKB-569, an irreversible inhibitor of the epidermal growth factor receptor: Phase 1 trial results in patients with advanced solid tumors

European Journal of Cancer. 2002;38:S64

Link1 Link2

A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumours

A.C. Tan, A.O.L. Seet, S.P. Choo, D.W.M. Tai, Y.C.J. Lam, W.T. Teng, C. Lim, K.H. Lim, M.C.H. Ng

Annals of Oncology. 2019;30:v178

Link1 Link2 Link3

Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies

Yook-Hwan Noh, Hyeong-Seok Lim, Jin-A Jung, Tae Hun Song, Kyun-Seop Bae

Cancer Chemotherapy and Pharmacology. 2014;75(1):97-109

Link1

Link2 Link3

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancer

H Cortés-Funes, C Mendiola, L Manso, E Ciruelos

Breast Cancer Research. 2009;11(S1):

Link1

Link2 Link3

First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung Cancers

M.G. Kris, T. Mok, S.-H.I. Ou, R.G. Martins, D.-W. Kim, Z. Goldberg, H. Zhang, I. Taylor, S.P. Letrent, P.A. Jänne

Annals of Oncology. 2012;23:xi34

Link1 Link2

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

Tomohiro Nishina, Shunji Takahashi, Ryota Iwasawa, Hidehisa Noguchi, Masayuki Aoki, Toshihiko Doi

Investigational New Drugs. 2017;36(3):424-434

Link1 Link2

Link3

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

M.G. Kris, D.R. Camidge, G. Giaccone, T. Hida, B.T. Li, J. O'Connell, I. Taylor, H. Zhang, M.E. Arcila, Z. Goldberg, P.A. Jänne

Annals of Oncology. 2015;26(7):1421-1427

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.